Covidien: Maximum repurchase price adjusted to 46.83 yuan per share.

Kexing Pharmaceuticals announced that the company will adjust the upper limit of the share repurchase price from 29.77 yuan/share to 46.83 yuan/share to ensure the smooth implementation of the repurchase plan. This adjustment does not require approval from the company's shareholders' meeting. Kexing Pharmaceuticals has previously repurchased 104,700 shares through the Shanghai Stock Exchange, accounting for 0.05% of the total share capital, with a total payment of 2.4392 million yuan. This adjustment complies with relevant laws and regulations, aims to safeguard the smooth progress of the repurchase plan, and will not affect the company's debt repayment and ongoing operational capabilities.